Announcement based on the procedures for acquisition or disposal of assets

  1. Name of the securities: AP Biosciences Inc.
  2. Trading date: Jan 10, 2018 to Apr 20, 2018
  3. Trading volume, unit price, and total monetary amount of the transaction:
    (1) Acquired on Jan 10, 2018—trading volume: 6,700,000 shares; NT$43.25 per unit; total monetary amount NT$289,775,000
    (2) Board of Director resolution on Apr 20, 2018—subscription of cash capital increase shares not exceeding 2,000,000 shares, NT$45 per unit, total monetary amount not exceeding NT$90,000,000 (actual unit of subscription and the authorized amount is at the CEO’s discretion)
  4. Gain (or loss) (not applicable in case of acquisition of securities): N/A
  5. Relationship with the underlying company of the trade: Subsidiary
  6. Current cumulative volume, amount, and shareholding percentage of holdings of the security being traded (including the current trade) and status of any restriction of rights (e.g., pledges): Total amount of 8,700,000 shares held based on the resolution of the board of directors; cumulative holding amount: NT$379,775,000; cumulative shareholding ratio: 72.5% (to actual transaction volume of 6,700,000 shares as of Apr 20, 2018)
  7. Current ratio of long or short term securities investment (including the current trade) to the total assets and shareholder’s equity as shown in the most recent financial statement and the operational capital as shown in the most recent financial statement: Proportion to total asset: 7.32%; Proportion of equity attributable to owners of the parent company: 7.50%; amount of working capital: NT$4,644,867,000
  8. Concrete purpose/objective of the acquisition or disposal: Long term investment
  9. Do the directors have any objections to the present transaction?: No
  10. Any other matters that need to be specified: None